Theravance Biopharma Ireland Limited, a subsidiary of Theravance Biopharma, Inc. (and Mylan N.V. Mylan N.V. (NASDAQ:MYL) announced the expansion of the companies’ current development and commercialization agreement for nebulized revefenacin to include China and certain adjacent territories. Revefenacin, marketed as YUPELRI® in the U.S., is a long-acting muscarinic antagonist (LAMA), which is the first and only once-daily, nebulized bronchodilator approved for the treatment of chronic obstructive pulmonary disease (COPD) in the U.S.
Technical Stock Analysis
Mylan N.V. (NASDAQ:MYL), a Healthcare sector firm, traded 10.89 Million shares in last trading session and stock added 0.60% with closing price of $18.32 per share. Company gross margins represents its total sales revenue minus its cost of goods sold (COGS), divided by the total sales revenue earned by the company, expressed as a percentage. And its good to know that the higher that percentage, the more the company retains on each dollar of sales, to service its other costs and the debt obligations, and Mylan N.V. (NASDAQ:MYL)’s gross margin stands at 39.80%.
Investment Worthy Stock or not?
For personal guess ROI is usually expressed as a percentage and is typically used for taking any financial decisions, for the purpose of comparing a Mylan N.V. (NASDAQ:MYL)’s profitability or to compare the efficiency of different investments, hence, MYL return on investment (ROI) is 3.50%.
52-Week Range are valuable stats for watching Mylan N.V. (NASDAQ:MYL)’s past year fluctuation as that gives investors an idea of how much the security has moved in the last year and whether it is trading near the top, middle or bottom of the range. Mylan N.V. (NASDAQ:MYL)’s stock value has moved between $16.65 – 39.83 in last one year.
Analysts mean target price for Mylan N.V. (NASDAQ:MYL) is $30.56 while analysts mean recommendation is 2.10.
Its weekly performance is 7.64% while year to date (YTD) performance is -33.14%.
Earnings per share growth is defined as the percentage change in normalised earnings per share over the previous 12 month period to the latest year end. It gives a good picture of the rate at which a company has grown its profitability. Mylan N.V. (NASDAQ:MYL)’s EPS growth this year is -57.40%. For best decision making investors should look at Mylan N.V. (NASDAQ:MYL)’s EPS growth for next year stands at 5.49%.